ASCO 2020

Area: Oncology

Location: Online, Virtual

Date: May 29 to May 31


Search in Scientific Content:
Date
Filters:
KEYNOTE-20
7:11

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL)

Presenter: John Kuruvilla
Oncology
Update on
14:57

Update on state-of-the-art therapy in lung cancer

Presenter: Solange Peters
Oncology
GU cancer
12:02

GU cancer highlights of ASCO 2020

Presenter: Ignacio Duran
Oncology
Melanoma h
19:40

Melanoma highlights of ASCO 2020

Presenter: Michael A. Postow
Oncology
Osimertini...
8:15

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

Presenter: David R. Spigel
Oncology
Trifluridi...
9:28

Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study

Presenter: Clélia Coutzac
Oncology
Highlights
20:32

Highlights of ASCO

Presenter: Jeffrey Weber
Oncology
First safe
8:49

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma

Presenter: Irene Reijers
Oncology
Maintenanc
10:18

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis

Presenter: Elizabeth R. Plimack
Oncology
Carfilzomi
4:22

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial

Presenter: Shaji Kumar
Oncology
Updated re
3:13

Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Presenter: Shaji Kumar
Oncology
Pembrolizu
3:56

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study

Presenter: Thierry Andre
Oncology
Immune che
7:58

Immune checkpoint inhibitor therapy in colorectal cancer: the lessons we learned from CheckMate-142 and KEYNOTE 177 trials

Presenter: Thierry Andre
Oncology

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria

SABCS 2018

2018-12-04 - 2018-12-08
San Antonio, United States

ESMO 2018

2018-10-19 - 2018-10-23
Munich, Germany

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States

ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria